RDY Dr. Reddy's Laboratories Limited

14.83USD-1.00%Mkt Cap: 12.36B USDP/E: 41.19

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, …

Institutional holders20 on file

Key Statistics

Company
Market Cap12.36B USD
Enterprise Value73.96B USD
Revenue (TTM)3.53B USD
Gross Profit1.90B USD
Net Income (TTM)458.56M USD
Revenue/Share0.71 USD
Last Price14.83 USD
Fiscal Year EndMar 2026
MR QuarterSep 2026
Employees27.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)41.19
P/E (Forward)22.38
PEG2.05
EV/EBITDA1.49
EV/Revenue20.95
P/S0.04
P/B18.07
EPS (TTM)0.0039 USD
EPS (Forward)0.0071 USD
52W Range
11.3681% of range15.67
52W High15.67 USD
52W Low11.36 USD
Profitability
Gross Margin52.77%
Oper. Margin9.12%
EBITDA Margin15.10%
Profit Margin12.76%
ROE11.36%
ROA7.40%
ROIC10.49%
ROCE12.17%
Growth
Revenue Growth-1.50%
Earnings Growth-35.70%
Cash Flow & Leverage
Operating CF607.36M USD
CapEx (TTM)411.20M USD
FCF Margin-2.00%
FCF Yield-0.57%
Net Debt-42.32M USD
Net Debt/EBITDA-0.08
Net Debt/FCF—
Balance Sheet
Debt/Equity0.21
Current Ratio1.93
Quick Ratio1.15
Book Value/Sh0.0088 USD
Cash/Share0.16 USD
Dividends
Fwd Div Rate0.08 USD
Trail. Div Rate8.00 USD
Div. Yield0.56%
5Y Avg Yield0.65%
Payout Ratio22.72%
Ex-Div DateJul 9, 2026
Pay DateAug 5, 2026
Splits
Last Split5:1
Split DateNov 5, 2024
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.82 USD
Upside (mean)-0.1%
Target Range12.66 USD – 16.16 USD
12.66-0.1% to mean16.16
# Analysts5
Ownership
Shares Out.833.66M
Float3.59B
Insiders0.00%
Institutions16.31%
Short Interest
Short Ratio7.9d
Short % Float3.69%
Short % Out.3.04%
Shares Short25.30M
Short (prev mo.)28.39M
Technical
SMA 5013.10 (+13.2%)
SMA 20013.29 (+11.6%)
Beta0.20
S&P 52W Chg12.08%
Avg Vol (30d)2.63M
Avg Vol (10d)2.54M
Technical Indicators
RSI (14)67.1
MACD0.4722
MACD Signal0.5100
MACD Hist.-0.0378
BB Upper15.46 USD
BB Middle14.46 USD
BB Lower13.47 USD
BB Width13.74%
ATR (14)0.2752 USD
Vol Ratio (20d)0.71x

About Dr. Reddy's Laboratories (NYSE: RDY)

›

Dr. Reddy's Laboratories (NYSE: RDY) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 27,527 employees.

The shares were at 14.83 USD on 19 November 2026, up 6.5% over 52 weeks. Its 52-week range is 11.36 USD to 15.67 USD: the price is 5.4% below the high and 30.5% above the low.

At a market capitalisation of 12.36B USD, it trades at 41.2 times trailing earnings and 22.4 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 67% for RDY. It pays a dividend yielding 0.56% (it pays out 23% of its earnings), against a median of 2.01% among the dividend payers in that peer group.

Dr. Reddy's Laboratories reports return on equity of 11.4%, an operating margin of 9.1% and revenue down 1.5% year over year.

It holds more cash than debt, a net cash position of 3.95B INR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 14.82 USD is 0.1% below the current price. The next earnings report is expected on 21 January 2027.